Illumina, Inc. vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Illumina, Inc. trades at $264.24 (market cap $40.43B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $25.97 (market cap $115.44M). The key difference: Illumina, Inc. is far larger — about 350.2× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| ILMN | KOLD | |
|---|---|---|
Market Cap | $40.43B | $115.44M |
Volume | 2,948,626 | 6,626,046 |
Sector | Health | Leveraged / Inverse |
52-Week High | $293.69 | $49.39 |
52-Week Low | $91.00 | $13.58 |
Typical Hold Time | 83 Days | 10 Days |
Enterprise Value | $41.79B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
KOLD is trading at $24.84, down 5.8% over the past 24 hours amid bearish technical signals. The stock faces strong selling pressure with moving averages indicating a bearish trend and oscillators in neutral territory. Recent news highlights natural gas market volatility driven by record production levels and geopolitical tensions in the Middle East affecting energy commodities.
The outlook remains challenging with technical indicators pointing to continued downward pressure. Investment opportunities may emerge if the stock finds support near current levels, but risks include ongoing natural gas price volatility and geopolitical uncertainties. The bearish technical setup suggests cautious positioning is warranted until clearer fundamental catalysts emerge.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →